CD19 and neoplasm: Another supporting data in Burkitt lymphoma exhibited the beneficial effects of lenalidomide accompanied by CD19-CAR-T cells in enhancing the anti-tumor cytotoxicity and IFN-γ production, which elicited an increased activity and infiltration of T cells in the tumor site and reduced tumor burden in treated mice [115].